This trial will test whether marine omega-3 fatty acids and 5-alpha-reductase inhibitors can help low-risk prostate cancer patients by slowing the progression of the disease.
1 Primary · 3 Secondary · Reporting Duration: 0-6-12 months
Experimental Treatment
120 Total Participants · 2 Treatment Groups
Primary Treatment: Drug (Dutasteride) intervention first · No Placebo Group · N/A
Age 35 - 75 · Male Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: